Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
NervousNelly, we are grateful that you read your tea leaves this morning, though it is a pity, those same tea leaves, failed to advise you that you would go in the GSK, site instead of your normal LGEN, site. Unfortunately, you failed to provide, any words of wisdom on the GSK, equity, which is just as well because LGEN, fundamentals, would not be relevant.
No matter what the word is on people who go by charts etc. With GSK settling the Zantac claim out of court with no claim of liability this has got to be good news for us long termers. I've already put my money where my mouth is this morning and added to my holding. GLA
As expected the sp, retraced with profit taking at 1600 level, which is where the long term upward sloping resistance line is situated . The recent Bollinger band high of 1631, was not breached, and the equity is falling back to the region of yesterday's Bollinger band high. Long term support for GSK, is situated at the up sloping trend line at 1500. DYOR.
Looks like others on the zoom were impressed. I’m very happy with my top up this morning. The fall was unwarranted, surprised that it changed round intraday but it doesn’t really matter as these are a long term hold. The market should start to appreciate gsk at some point and I will be here when it does.
[GSK] I joined the Zoom call at 11.00 to see if I could detect anything in the fundamentals that would justify the initial fall in share price. I couldn't. The full year figures were good but were expected to be; what was new was the rise in the sales, profit and eps growth in the period 2026 - 31. They expect 12 new product launches in this period and that margins will remain "stable" despite loss of patent protection on some drugs. What came out was that these are "risk adjusted" (kept modest) projections. They did show a non risk adjusted growth projection which phenomenal. With debt coming down, growth going up and margins not deteriorating I broke my usual rules and increased my holding at 1534p during the meeting. This stock is cheap relative to other pharmaceutical companies and doing well in a couple of well defined niches, yes, I know Zantac overshadows the company but with free cash flow of over £3.4b per year would they not survive if the drug was proved to have a very low rate of carcinogenesis? I see the stock is going up post the meeting so Romeike you may yet see your £18 - 20 level.
Because there was a run up ahead of results in anticipation they would be good. Some of those are now profit taking on their call and closing long contracts. I'm expecting a move back up towards 18-20 level once the news from Delaware is out.
I’m going to keep buying. In comparison to its peers gsk is undervalued. Nothing to warrant a drop today.
So unloved, don’t understand.
Can't believe we're down after that update. Same reaction as the last good update!
ZANTAC , Liability???
What didn’t market like?
July 12th this year!
Woha ...what is all this share enthusiasm?
Older What’s the date?
This stick is frustrating, but it hasn’t broken my faith yet. I’m still buying. If we don’t get a boost from the end of the litigation I’ll reassess then.
....and still our SP falls!
I am going to mark a date in my diary and if this is not then subject to a bid or at least £17.50, I shall reluctantly say goodbye.
Citi raised its target price on GSK from 1535p to 1700p. The bank has now increased its core earnings per share estimates for 2030 to 2035 by between 19% and 43%. They particularly like the recent Bellus and Aiolos respiratory deals addressing de-risked targets in a core therapeutic area of competence for GSK. Citi has also raised its forecasts for ViiV - “assuming the next generation therapies with larger dosing windows translate into higher adoption rates”.
...shows Citi giving us the thumbs up after many years. Let's hope a few more big institutions come out in support and this SP finally firms up.
Some of the most robust evidence (suggesting no evidence of a link between ranitidine with cancer) was published in Sept 2023 in the The Journal of the American Medical Association (JAMA). Link below -
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509724/
I have no idea how the ambulance chasers are going to dismiss this large multinational credible study, especially as its validity is supported by the publication in a leading peer reviewed American journal.
Another unjustified drop in SP yesterday, for a hearing in Delaware we’ve known about for some time? GSKs defence seems pretty strong.. Yes, there is a theoretical risk that NDMA in ranitidine could increase the risk of cancer, hence its removal from market, but as GSK are saying (quite correctly) there is now an increasing body of robust evidence, in large real world observational studies, (since the litigation was initially raised) which show no increase in cancer rates over the PPIs, or famotidine.. (one of many papers below)
https://pubmed.ncbi.nlm.nih.gov/34251045/
I’m still at a loss to understand why such a sustained hit on the SP. You can’t win a case purely on theoretical risk, especially if the subsequent robust clinical studies have disproven the theory…IMHO of course…
Feels like everyone thinks the drop in SP is overdone , but guess we'll have to wait for the judges now to agree
Analysts finally catching on to what we have known for the past 6-12 months.
The chance to buy at under £14 was the biggest giveaway since being able to buy Shell for under £10.
UBS raises GSK to ‘buy’ rating from ‘sell’ and increase price target from 1310p to 1860p
UBS cuts AstraZeneca to ‘sell’ rating from buy reducing its price target from 13000p to 10700p.
Ahead of GSK’s full year results, the stock trades at nine times earnings, compared with sector peers who trade at a multiple of 15. They continue to view the current discount to peers as unwarranted and largely attributable to misguided assumptions on the potential cost of Zantac litigation. This has disproportionately overshadowed the improved and increasingly attractive growth story GSK delivered in 2023.
The broker has lifted its target price from 1850p to 2000p and kept a ‘buy’ rating
GSK has received a buy recommendation and a healthy price target upgrade from analysts at Deutsche Bank, which has the UK pharma as a top pick in the sector.
Deutsche Bank’s target price for GSK rises to 1850p from 1700p
Jefferies have been listening to Dame Emma.
Therefore raising of SP to 1900pence.
Like to see 1900pence SP ASAP
Stay positive - it's a new Year...